Navigation Links
PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
Date:1/10/2014

SEATTLE, Jan. 10, 2014 /PRNewswire/ -- PhaseRx, Inc., an RNA therapeutics company, today announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development.

(Logo: http://photos.prnewswire.com/prnh/20140110/SF44129LOGO)

Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx.  He has directed numerous programs ranging from research to GMP manufacture of clinical trials materials, including nanoparticle-based delivery vehicles for siRNAs. In this new position, Dr. Houston will lead PhaseRx's therapeutics program, which focuses on the advancement of its SMARTT Polymer Technology® mRNA nanoparticles.

"Mike is a great addition to the PhaseRx team as we focus on the advancement of our SMARTT Polymer Technology RNA programs into clinical development," said Robert Overell, Ph.D., President and Chief Executive Officer at PhaseRx. "Mike's experience in the synthesis, manufacture and production of RNA therapeutics including nanoparticle-based formulations, will accelerate our efforts to apply SMARTT technology to address the significant unmet treatment need in orphan liver diseases."

Dr. Houston joins PhaseRx from Marina Biotech where he served as Vice President, Chemistry and Formulations and focused on the development of siRNAS and single stranded oligonucleotides. He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations. Dr. Houston received a Ph.D. in bio-organic chemistry and a B.Sc. with honours in chemistry from the University of Waterloo, Ontario, Canada.

PhaseRx's SMARTT Polymer Technology (SMARTT) mediates endosome escape and mRNA delivery into cytoplasm, overcoming the key stumbling block to the delivery of mRNA drugs into cells.  SMARTT has been developed into an industrialized system that is well-tolerated in small and large animal models, does not induce innate immunity and provides robust, scalable manufacture. PhaseRx is evaluating several disease targets for SMARTT and will be selecting its lead program in 2014.

About PhaseRx
PhaseRx is privately held RNA therapeutics company developing treatments for orphan liver disease. The Company is utilizing its proprietary SMARTT Polymer Technology®, which offers the ability to deliver messenger RNA therapeutics predictably to selected tissues in vivo, thereby unlocking the value of mRNA as a new therapeutic modality. PhaseRx is headquartered in Seattle, Wash. For more information, visit www.phaserx.com.  

Contact: 
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com                                  
206.769.9219

 


'/>"/>
SOURCE PhaseRx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
2. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
3. Mylan Appoints Adele Gulfo as EVP, Global Collaboration and Strategic Operations
4. Lakewood-Amedex Inc. Appoints Geoffrey F. Cox To Its Board Of Directors
5. Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
6. Auspex Raises $35 Million And Appoints Industry Veteran Gerald Proehl To Its Board of Directors
7. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
8. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
9. MIMETAS Appoints BHI Entrepreneur-in-Residence Todd Chappell as General Manager, U.S. Affairs
10. Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
11. Concord Medical Announces Results of 2013 Annual General Meeting; Appoints New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2019)... (PRWEB) , ... October 18, 2019 , ... Beginnings Treatment ... to act as the official sponsor of the Alcohol and Other Drug Awareness ... to empower students to make informed decisions around alcohol and other drugs through individual ...
(Date:10/19/2019)... ... October 19, 2019 , ... A popular performer and ... of educational programming. "Behind the Scenes" with Laurence Fishburne has the goal of educating ... large today. Recently, the show has turned its attention to the world of healthcare. ...
(Date:10/17/2019)... ... ... prominent features on a person is the ears. There are times when people are born ... This can cause a great deal of embarrassment to teens as well as adults so ... In order to help patients get the change they desire when it comes to the ...
Breaking Medicine Technology:
(Date:10/19/2019)... ... ... Today, Guide Dogs for the Blind (GDB), the national nonprofit ... people, guide dogs and communities, kicks off the organization’s momentous, weekend-long 2019 Guide Dogs ... community for the event to celebrate GDB’s mission and to experience what the city ...
(Date:10/17/2019)... ... October 17, 2019 , ... Knotty Roller, the affordable all-in-one muscle recovery ... campaign goal– raising more than $20,000 in only eleven hours after launching on ... be the first to enjoy the ease of use and versatility of our product,” ...
(Date:10/17/2019)... ... October 17, 2019 , ... A clinical article reviewing the ... Cosmetic Surgery Paper Award at Plastic Surgery - The Meeting 2019 in San Diego ... 6 Years,” was authored by Larry S. Nichter, M.D., Robert A. Hardesty, M.D., and ...
(Date:10/15/2019)... ... October 14, 2019 , ... Khalieghya Dandie-Evans, a liver ... ride atop the Donate Life Rose Parade® float in the 131st Rose Parade® on ... tissue donation across Northern California and Northern Nevada, the organization’s service area. , Khalieghya, ...
(Date:10/15/2019)... CHURCH, Va. (PRWEB) , ... October 15, 2019 ... ... Products:, Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, ... the recent Instructions for Use (IFU) guidance have on new drug applications and ...
Breaking Medicine News(10 mins):